Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma

Completed · Phase 1/Phase 2

Conditions studied: Epidemic Kaposi's Sarcoma, Recurrent Kaposi's Sarcoma

In brief

RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill their tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of interleukin-12 in treating patients with AIDS -related Kaposi's sarcoma.

Key facts

Study ID

NCT00019188

Run by

National Cancer Institute (NCI)

Starts

1997-01-01

Expected to finish

2007-03-01

Last updated by the study team

2024-03-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Medicine Branch — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.